Lunai Bioworks (LNAI) Receivables - Net (2012 - 2025)

Lunai Bioworks (LNAI) posted quarterly Receivables - Net of $964389.0 for Q1 2025, down 10.17% quarter-over-quarter from $1.1 million in Q4 2023.

Lunai Bioworks (LNAI) Receivables - Net (2012 - 2025) Analysis & Trends

Lunai Bioworks' Receivables - Net history runs 7 years deep, the most recent figure standing at $964389.0 for Q1 2025.

In Q1 2025, Receivables - Net changed N/A year-over-year to $964389.0; the TTM figure through Mar 2025 stood at $964389.0 (changed N/A YoY), while the FY2016 annual figure was $695418.0, up 60.93% from the prior year.
Receivables - Net for Q1 2025 stood at $964389.0, down from $1.1 million in the prior quarter.
The five-year high for Receivables - Net was $1.1 million in Q4 2023, with the low at $964389.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00

Download Data